Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 79

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 79
---
 potent therapeutics in proven lipid-based particles, such as those
used in Doxil®. By encapsulating potent therapeutics, our approach is intended to enable controlled release, improve biodistribution
to the affected tissues, and extend systemic circulation time. These enhancements may collectively improve the therapeutic index by increasing
efficacy while potentially reducing systemic exposure and associated toxicities. However, there can be no assurance that features will
be replicated in clinical studies or translate into meaningful patient outcomes.

References

| 1. | De Villiers MM, Aramwit P, Kwon GS. Nanotechnology 
 in Drug Delivery. Springer, 2008.                  |

| 2. | Allen TM, Cullis PR. Liposomal drug delivery systems:                                  
 From concept to clinical applications. Advanced Drug Delivery Revew. 2013;65(1):36–48. |

| 3. | He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution                                                                   
 and urinary excretion of mesoporous silica nanoparticles: Effects of particle size and PEGylation. Small. 2011;7(2):271–280. |

| 4. | Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK,                                                       
 Hua S. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 2015;6:286. |

| 5. | EMA Assessment Report – Comirnaty (BioNTech/Pfizer). 
 EMA/707383/2020.                                     |

| 6. | Baden LR, El Sahly HM, Essink B, et al. Efficacy and                                                 
 safety of the mRNA-1273 SARS-CoV-2 vaccine. N The New England Journal of Medicine. 2021;384:403–416. |

| 7. | Arcturus Therapeutics Press Releases, 2020–2021. |

| 8. | Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles           
 for mRNA delivery. Nature Reviews Materials. 2021;6:1078–1094. |

<div align='center'>47

Product Pipeline in Development</div>

Through LipoVation,
our operating subsidiary which we acquired in July 2024, we are developing programs in infectious diseases, oncology and vaccination.

We intend to use tiny, specially designed